Congress 2025: United Therapeutics to Present Clinical Data at PVRI Annual Event
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that it will present five posters showcasing data from its commercial and development portfolio in pulmonary hypertension (PH) at the Pulmonary Vascular Research Institute (PVRI) 2025 Annual Congress. The event will be held from January 29 to February 1, 2025, in Rio de Janeiro. Additionally, United Therapeutics professionals will take part in two speaking sessions during the congress.
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, is pleased to announce its participation in the upcoming Pulmonary Vascular Research Institute (PVRI) 2025 Annual Congress, set to take place from January 29 to February 1, 2025, in Rio de Janeiro. The company will present five posters highlighting data from its commercial and development portfolio in pulmonary hypertension (PH). Additionally, United Therapeutics professionals will engage with the scientific community during two speaking sessions at the congress. The event provides an invaluable opportunity for scientific exchange, and United Therapeutics is also excited to sponsor key networking events designed to foster collaboration and mentorship in the pulmonary hypertension field.
Key Presentations at PVRI Congress
United Therapeutics will showcase several key pieces of research at the congress, including posters that highlight both real-world data and clinical trial results related to their innovative therapies for pulmonary hypertension. One of the key posters will focus on real-world dosing of Tyvaso® DPI (treprostinil inhalation powder) in both pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). This study, led by researchers including Burger, El-Kersh, Parikh, and others, examines the practical use and dosing patterns of Tyvaso DPI in these patient populations, contributing valuable insights into its therapeutic application outside of controlled trial settings.
Another important presentation is titled “BREEZE Optional Extension Phase: Long-Term Outcomes with Tyvaso DPI in Patients with Pulmonary Arterial Hypertension.” This research, conducted by Spikes, Bajwa, Burger, Ramani, and colleagues, focuses on the long-term outcomes for patients with PAH who have been treated with Tyvaso DPI. This study’s findings will provide critical information on the sustainability of treatment benefits in PAH patients over extended periods of time.
Interim results from the PHINDER study will also be shared, offering important insights into pulmonary hypertension screening for patients with interstitial lung disease. This study, led by Beck, Broderick, Chavarria, and others, aims to identify potential methods for detecting PH earlier in patients suffering from interstitial lung disease, ultimately aiming for earlier intervention and improved patient outcomes.
Additionally, United Therapeutics will present a subgroup analysis of the TRIUMPH study, focusing on the use of inhaled treprostinil for treating PAH in intermediate-high-risk patients. This study, authored by Argula, El-Kersh, Estrada, McLaughlin, Hong, Thrasher, and others, provides further insights into the efficacy of inhaled treprostinil in patients with varying levels of disease severity.
Finally, the company will present data from the ARTISAN study, which explores the patient-reported experience of participants receiving PAH treatments. This poster, led by Tomson, Gunzenhauser, Daczkowski, and their team, will focus on understanding patient perspectives and quality of life while participating in clinical trials for PAH treatments.
Speaking Sessions and Networking Opportunities
In addition to the poster presentations, United Therapeutics will have a significant presence at the speaking sessions. Kellie Morland, PharmD, from United Therapeutics, will co-chair a session on Real World Evidence/Real World Data, which will take place on Wednesday, January 29, from 10:40 to 11:15 AM in Oceania IX. This session will explore the growing importance of real-world data in understanding the long-term effectiveness of treatments and will provide valuable insights into how data from clinical practice can inform future research.
Another key session, “Challenges of Clinical Trial Design, Conduct & Endpoints,” will feature insights from C.Q. Deng, M.D., Ph.D., MPH, from United Therapeutics. This session, scheduled for Wednesday, January 29, from 12:22 to 12:30 PM in Oceania IX, will focus on the challenges of designing, conducting, and interpreting clinical trials, particularly in the context of pulmonary hypertension.
Sponsored Events: Empowering Women and Early Career Professionals
United Therapeutics is proud to sponsor two important networking events at the PVRI congress. The first, the Women in PH Luncheon, will take place on Friday, January 31, from 11:15 AM to 1:00 PM. This event was created to support women in the field of pulmonary hypertension and provide opportunities for education and networking. It aims to foster an inclusive, diverse community while strengthening professional connections among women in PH.
The second sponsored Congress, the Career Catalyst Luncheon: Speed Mentoring for Early Career PH Professionals, will be held on Thursday, January 30, from 11:10 AM to 1:00 PM. This event provides early-career PH professionals with micro-mentoring opportunities, allowing them to connect with senior and mid-career researchers in a welcoming and informal setting. The goal of this luncheon is to facilitate networking, provide career guidance, and build a strong support system for the next generation of PH professionals.
About Tyvaso® Inhalation Solution and Tyvaso DPI® Inhalation Powder
Tyvaso® Inhalation Solution and Tyvaso DPI® Inhalation Powder are prostacyclin mimetics indicated for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Tyvaso is specifically designed to improve exercise ability in patients with PAH (WHO Group 1) and PH-ILD (WHO Group 3). Both formulations of Tyvaso have been shown to be effective in clinical studies, predominantly involving patients with idiopathic or heritable PAH, as well as PAH associated with connective tissue diseases and idiopathic interstitial pneumonia.
Tyvaso’s inhaled formulations have been pivotal in improving patient outcomes, and ongoing research continues to explore its broader potential across different populations.
United Therapeutics remains committed to advancing the treatment and understanding of pulmonary hypertension, and the PVRI 2025 Annual Congress is an essential platform for sharing these ongoing developments.
